Join the club for FREE to access the whole archive and other member benefits.

Life Biosciences

Drug development company promoting longevity and finding treatments for age-related diseases

Founded in 2017 and headquartered in Boston, MA, Life Biosciences is pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop pharmaceutical treatments with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs.

Aging is the biggest risk factor for almost every chronic disease. Ground-breaking research over the past decade has shown that aging is a modifiable risk factor that can be targeted therapeutically. Developing medicines that modify aging biology to prevent, delay, and/or reverse diseases of aging has the potential to transform the practice of medicine.

Visit website:




Details last updated 04-May-2019

Life Biosciences is also referenced in the following:

David Sinclair

Harvard professor. Author of Lifespan.

People at Life Biosciences

Jerry McLaughlin

Chief Executive Officer at Life Biosciences

Tristan Edwards

Co-Founder of Life Biosciences, Executive Chairman at Proto Axiom

Sharon Rosenzweig-Lipson

Chief Scientific Officer at Life Biosciences

Life Biosciences News

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years


Life bio's gene therapy reboots cells, offering hope for vision loss and beyond

GlobeNewswire - 23-Apr-2023

Epigenetic reprogramming restored in primates, now paving way for human trials


Life Biosciences raises funding to develop innovative therapies against ageing biology

Longevity Technology - 06-Jan-2022

Invests $82 million in research platforms, aiming to prevent or reverse age-related diseases


Investing in the Longevity industry

Longevity Technology - 18-Sep-2019

Edwards believes 20–30 years will be added to the average lifespan with none of the ageing diseases


Today's 50 year-olds may live another 100 years

Forbes - 26-Aug-2019

Good summary of some major investments in life extension companies

Topics mentioned on this page:
Laboratory Automation